Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022, 166(3):243-250 | DOI: 10.5507/bp.2022.002

The use of biomarkers in the diagnosis and treatment of obstruction of the upper urinary tract in children

Zuzana Seifriedovaa, Hana Flogelovab, Jan Sarapatkaa, Oldrich Smakala, Vladimir Student Jr.a
a Department of Urology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic

Antenatal hydronephrosis, dilatation of the upper urinary tract (UUTD), is a common finding on prenatal ultrasound. One of the most common causes is ureteropelvic junction (UPJ) obstruction. Although such prenatally diagnosed UUTD resolves spontaneously in most newborns, further examination of these children is advocated to prevent possible irreversible kidney damage, and ultrasound is mainly used for this. If the dilatation persists or becomes symptomatic, it is necessary to proceed to other relatively demanding and invasive diagnostic examinations for these small patients, where the question of the right timing of indications for possible surgical solutions is still unclear. For this reason, various biomarkers have been investigated in a number of clinical trials as potential mini-invasive diagnostic tools for determining when upper urinary tract dilatation in such children poses a threat to the developing kidneys and they should be operated on, and vice versa, when to proceed conservatively. The aim of this article is to review the findings on and current issues with the use of biomarkers in the diagnosis and treatment of UPJ obstruction in children.

Keywords: hydronephrosis, obstruction, ureteropelvic junction, biomarkers

Received: May 13, 2021; Revised: November 28, 2021; Accepted: January 21, 2022; Prepublished online: February 3, 2022; Published: September 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Seifriedova, Z., Flogelova, H., Sarapatka, J., Smakal, O., & Student, V. (2022). The use of biomarkers in the diagnosis and treatment of obstruction of the upper urinary tract in children. Biomedical papers, 166(3), 243-250. doi: 10.5507/bp.2022.002
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Radmayr C, Bogaert G, Dogan HS, Kočvara R, Nijman JM, Stein R, Tekgül S, 't Hoen LA, Quaedackers J, Silay MS, Undre S. EAU Guidelines on Pediatric Urology. In: European Association of Urology Guidelines, 2018 edition. European Association of Urology, 2018, p. 58. ISBN 978-94-92671-01-1.
    2. Peters C, Chevalier R. Congenital urinary obstruction: Patho­physiology and clinical evaluation. In: Campbell-Walsh Urology: Pediatric urology [online]. Elsevier, 2015 [vid. 2021-02-02]. Available from: https://expertconsult.inkling.com/read/wein-campbellwalsh-urology-pediatric-urology-1st/chapter-14/clinical
    3. Lebowitz, RL, Griscom NT. Neonatal hydronephrosis: 146 cases. Radiol Clin North Am 1977;15:49. Go to original source... Go to PubMed...
    4. Radmayr C, Bogaert G, Dogan HS, Nijman JM, Rawashdeh YFH, Silay MS, Stein R, Tekgül S. EAU Guidelines on Pediatric Urology. In: European Association of Urology [online]. Uroweb, 2021 [vid. 2021-02-24]. Available from: https://uroweb.org/guideline/paediatric-urology/
    5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95. Go to original source... Go to PubMed...
    6. Yu L, Zhou L, Li Q, Wu B, Brooks JD, Sun H. J Elevated urinary lipocalin-2, interleukin-6 and monocyte chemoattractant protein-1 levels in children with congenital ureteropelvic junction obstruction Pediatr Urol 2019;15:44.e1-7. Go to original source... Go to PubMed...
    7. Bienia¶ B, Sikora P. Potential novel biomarkers of obstructive nephropathy in children with hydronephrosis. Dis Markers 2018;2018:1015726. Go to original source... Go to PubMed...
    8. Gupta S, Jackson AR, DaJusta DG, McLeod DJ, Alpert SA, Jayanthi VR, McHugh K, Schwaderer AR, Becknell B, Ching CB. Urinary antimicrobial peptides: potential novel biomarkers of obstructive uropathy. J Pediatr Urol 2018;14:238.e1-6. Go to original source... Go to PubMed...
    9. Karakus S, Oktar T, Kucukgergin C, Kalelioglu I, Seckin S, Atar A, Ander H, Ziylan O. Urinary IP- 10, MCP-1, NGAL, cystatin-C, and KIM-1 levels in prenatally diagnosed unilateral hydronephrosis: the search for an ideal biomarker. Urology 2016;87:185-92. Go to original source... Go to PubMed...
    10. Noyan A, Parmaksiz G, Dursun H, Euer SS, Anarat R, Cengiz N. Urinary NGAL, KIM-1 and L-FABP concentrations in antenatal hydronephrosis. J Pediatr Urol 2015;11:249.e1-6. Go to original source... Go to PubMed...
    11. Cost NG, Noh PH, Devarajan P, Ivancic V, Reddy PP, Minevich E, Bennett M, Haffner C, Schulte M, DeFoor WR Jr. Urinary NGAL levels correlate with differential renal function in patients with ureteropelvic junction obstruction undergoing pyeloplasty. J Urol 2013;190:1462-7. Go to original source... Go to PubMed...
    12. Wasilewska A, Taranta-Janusz K, Dębek W, Zoch-Zwierz W, Kuroczycka-Saniutycz E. KIM- 1 and NGAL: new markers of obstructive nephropathy. Pediatr Nephrol 2011;26:579-86. Go to original source... Go to PubMed...
    13. Madsen MG, Nørregaard R, Palmfeldt J, Olsen LH, Frøkiaer J, Jørgensen TM. Urinary NGAL, cystatin C, β2-microglobulin, and osteopontin significance in hydronephrotic children. Pediatr Nephrol 2012;27:2099-106. Go to original source... Go to PubMed...
    14. Fendereski K, Nabighadim A, Seyedtabib M, Daryabari SS, Haghi-Ashtiani MT, Kajbafzadeh AM. Comparing predictive values of carbohydrate antigen 19-9, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1 in 161 patients with ureteropelvic junction obstruction. Pediatr Nephrol 2021;36(3):631-38. Go to original source... Go to PubMed...
    15. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53e5. Go to original source... Go to PubMed...
    16. Vestergaard EM, Wolf H, Orntoft TF. Increased concentrations of genotype-interpreted Ca 19-9 in urine of bladder cancer patients mark diffuse atypia of the urothelium. Clin Chem 1998;44:197e204. Go to original source...
    17. Aoki D, Nomata K, Kanda S, Sawase K, Kanetake H, Saito Y, Tsuda N. A case of pyonephrosis caused by ureteral stones with elevated serum levels of CA19-9. Hinyokika Kiyo 1999;45: 629e32.
    18. Suzuki K, Muraishi O, Tokue A. The correlation of serum carbohydrate antigen 19-9 with benign hydronephrosis. J Urol 2002;167:16e20. Go to original source...
    19. Taki T, Honda N, Yamada Y, Hibi H, Mitsui K, Matsuura O, Yoshikawa K. CA19-9-producing transitional cell carcinoma of the renal pelvis: a case report. Hinyokika Kiyo 2001;47:191e4.
    20. Nabavizadeh B, Khorramirouz R, Amini E, Pishgar F, Hojjat A, Kajbafzadeh AM. Value of urinary carbohydrate antigen 19-9 to predict failure of conservative management in children with ureteropelvic junction obstruction. J Pediatr Surg 2019;54:1650-3. Go to original source... Go to PubMed...
    21. Atar A, Oktar T, Kucukgergin C, Kalelioglu I, Seckin S, Ander H, Ziylan O, Kadioglu TC. The roles of serum and urinary carbohydrate antigen 19-9 in the management of patients with antenatal hydronephrosis. J Pediatr Urol 2015;11:133.e1-5. Go to original source... Go to PubMed...
    22. Kajbafzadeh AM, Elmi A, Talab SS, Emami H, Esfahani SA, Saeedi P. Urinary and serum carbohydrate antigen 19-9 as a biomarker in ureteropelvic junction obstruction in children. J Urol 2010;183:2353-60. Go to original source... Go to PubMed...
    23. Merrikhi A, Bahraminia E. Association of urinary transforming growth factor-β1 with the ureteropelvic junction obstruction. Adv Biomed Res 2014;3:123. Go to original source... Go to PubMed...
    24. Sager C, Lopez JC, Duran V, Burek C, Perazzo E. Transforming growth factor-beta1 in congenital ureteropelvic junction obstruction: diagnosis and follow-up. Int Braz J Urol 2009;35:315-23; discussion 323-5. Go to original source... Go to PubMed...
    25. Taha MA, Shokeir AA, Osman HG, Abd El-Aziz Ael-A, Farahat SE. Pelvi-ureteric junction obstruction in children: the role of urinary transforming growth factor-beta and epidermal growth factor. BJU Int 2007;99:899-903. Go to original source... Go to PubMed...
    26. Palmer LS, Maizels M, Kaplan WE, Filrit CF, Cheng EY. Urine levels of transforming growth factor-beta 1 in children with ureteropelvic junction obstruction. Urology 1997;50:769-73. Go to original source... Go to PubMed...
    27. El-Sherbiny MT, Mousa OM, Shokeir AA, Ghoneim MA. Role of urinary transforming growth factor-beta1 concentration in the diagnosis of upper urinary tract obstruction in children. J Urol 2002;168:1798-800. Go to original source... Go to PubMed...
    28. Sadeghi-Bojd S, Alijani E, Mahdavian MS. Mean urinary cytokine MCP-1 in children with urinary tract obstruction and healthy children. Nephro-Urol Mon 2018;10:e63607. Go to original source...
    29. Madsen MG, Nørregaard R, Palmfeldt J, Olsen LH, Frøkiaer J, Jørgensen TM. Epidermal growth factor and monocyte chemotactic peptide-1: potential biomarkers of urinary tract obstruction in children with hydronephrosis. J Pediatr Urol 2013;9:838-45. Go to original source... Go to PubMed...
    30. Taranta-Janusz K, Wasilewska A, Dębek W, Waszkiewicz-Stojda M. Urinary cytokine profiles in unilateral congenital hydronephrosis. Pediatr Nephrol 2012;27:2107-13. Go to original source... Go to PubMed...
    31. Grandaliano G, Gesualdo L, Bartoli F, Ranieri E, Monno R, Leggio A, Pradies G, Caldarulo E, Infante B, Schena FP. MCP- 1 and EGF renal expression and urine excretion in human congenital obstructive nephropathy. Kidney Int 2000;58:182-92. Go to original source... Go to PubMed...
    32. Mohammadjafari H, Rafiei A, Mousavi SA, Alaee A, Yeganeh Y. Role of urinary levels of endothelin-1, monocyte chemotactic peptide-1, and N-acetyl glucosaminidase in predicting the severity of obstruction in hydronephrotic neonates. Korean J Urol 2014;55:670-6. Go to original source... Go to PubMed...
    33. Mohammadjafari H, Rafiei A, Kosaryan M, Yaganeh Y, Hosseinimehr SJ. Determination of the severity of ureteropelvic junction obstruction using urinary epidermal growth factor and kidney injury molecule 1 levels. Biomark Med 2014;8:1199-206. Go to original source... Go to PubMed...
    34. Gerber C, Harel M, Lynch ML, Herbst KW, Ferrer FA, Shapiro LH. Proximal tubule proteins are significantly elevated in bladder urine of patients with ureteropelvic junction obstruction and may represent novel biomarkers: a pilot study. J Pediatr Urol 2016;12:120.e1-7. Go to original source... Go to PubMed...
    35. Li Z, Zhao Z, Liu X, Su Z, Shang X, Wen J. Prediction of the outcome of antenatal hydronephrosis: significance of urinary EGF. Pediatr Nephrol 2012;27:2251-9. Go to original source... Go to PubMed...
    36. Krensky AM, Ahn YT. Mechanisms of disease: regulation of RANTES (CCL5) in renal disease. Nat Clin Pract Nephrol 2007;3(3):164-70. Go to original source... Go to PubMed...
    37. Andreucci M, Faga T, Pisani A, Perticone M, Michael A. The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. Eur J Intern Med 2017;39:1-8. Go to original source... Go to PubMed...
    38. Shokeir AA, Taha MA. Role of urinary tubular enzymes in evaluation of children with ureteropelvic junction narrowing under conservative management. Urology 2009;73:1016-20. Go to original source... Go to PubMed...
    39. Taha MA, Shokeir AA, Osman HG, Abd El-Aziz Ael-A, Farahad SE. Obstructed versus dilated nonobstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes. J Urol 2007;178:640-6. Go to original source... Go to PubMed...
    40. Gupta S, Nicassio L, Junquera GY, Jackson AR, Fuchs M, McLeod D, Alpert S, Jayanthi VR, DaJusta D, McHugh KM, Becknell B, Ching CB. Impact of successful pediatric ureteropelvic junction obstruction surgery on urinary HIP/PAP and BD-1 levels. J Pediatr Urol 2020;16(5):592.e1-592.e7. Go to original source... Go to PubMed...
    41. Devarakonda CKV, Shearier ER, Hu C, Grady J, Balsbaugh JL, Makari JH, Ferrer FA, Shapiro LH. A novel urinary biomarker protein panel to identify children with ureteropelvic junction obstruction - A pilot study. J Pediatr Urol 2020;16(4):466.e1-466.e9. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content